-
Dr. Zhiren Chen: 3-year follow-up data from the START-FIT trial, showing an ORR of 67% for local advanced liver cancer patients
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China. In recent years, with the continuous improvement of diagnosis and treatment, the misdiagnosis rate and mortality of early-stage HCC have greatly decreased. However, many patients are already at an advanced stage when liver cancer is detected, making curative treatment impossible. For these…
-
How to choose the maintenance treatment plan after HSCT for R/R malignanthematological patients?
Relapse/refractory (R/R) has always been a difficult point in the clinical treatment of malignant hematological tumors. Hematopoietic stem cell transplantation (HSCT) is an important treatment for these patients to achieve long-term survival. Subsequent maintenance treatment is essential to consolidate the effects of HSCT and prevent disease recurrence. Therefore, researchers have been focusing on optimizing the…
-
Dr. Xingyu Cao: Post-transplant maintenance therapy with Chidamide in T-ALL patients is expected to reduce relapse and improve survival
Acute T-cell lymphoblastic leukemia (T-ALL) is a highly heterogeneous malignant tumor of the hematopoietic system caused by the malignant transformation of T-cell precursors. It has significant differences from B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in clinical features, cellular genetics, molecular biology, and abnormal signal transduction pathways. T-ALL accounts for 10%-15% in children and 20%-25% in…
-
Dr. Hui Wang: Unlocking a New Approach to MRD Testing in Acute Myeloid Leukemia
The 49th European Bone Marrow Transplantation Annual Meeting (EBMT 2023) took place in Paris, France, from April 23 to 26, 2023. Experts and scholars from various countries gathered to present exciting advancements in research. In the field of blood tests, the fifty-year anniversary of flow cytometry coincided with this year’s conference. Over the past half-century,…
-
Dr. Min Xiong: Incorporating Cytarabine in the Pre-treatment for Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemia with Extramedullary Disease is Safe and Effective
Allogeneic hematopoietic stem cell transplantation is among the most effective methods for treating malignant hematopoietic tumors. However, for extramedullary leukemia, even with high-intensity chemotherapy and transplantation, the recurrence rate remains high. To improve the prognosis, it’s essential to optimize the pre-treatment plan and reduce recurrence.At this EBMT annual meeting,Dr. Min Xiong from Hebei Yanda Ludaopei Hospital reported a…
-
Dr. Huibiao Zhang: ThreeOsimertinib Adjuvant Studies Shine at ELCC, Adding New Evidence for Early-Stage Lung Cancer Treatment
The 2023 European Lung Cancer Congress (ELCC) was held from March 29th to April 1st, in a combined online and offline format in Copenhagen, Denmark. Professor Nicolas Girard from the Curie Institute in Paris, France, presented the 3-year data update (Abstract 84O) of the CheckMate 816 study on neoadjuvant immune combined with chemotherapy in the…
-
Dr. Zhengfei Zhu: Can EGFR-TKI Combined with Local Consolidative Therapy Achieve “1+1＞2”?
The 2023 European Lung Cancer Congress (ELCC) is taking place in Copenhagen, the capital of the fairy tale kingdom of Denmark. On the first day of the conference, a session of oral presentations showcased the Phase II randomized study data on EGFR-TKI combined with local consolidative therapy for treating EGFR mutant metastatic non-small cell lung…
-
The urology team of West China Hospital has selected multiple studies for the 2023 EAU conference
The 38th European Association of Urology (EAU23) Annual Meeting took place from March 10th to 13th, 2023, in Milan, Italy, the fashion capital of the world. The EAU Annual Meeting is one of the most closely watched urological conferences in Europe and even globally, attracting over 15,000 urology experts from around the world each year.…
Connecting Medical Expertise through Media